Chemomab Therapeutics Ltd. (CMMB)
Largest Insider Buys in Sector
CMMB Stock Price History Chart
CMMB Stock Performance
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was …
Insider Activity of Chemomab Therapeutics Ltd.
Over the last 12 months, insiders at Chemomab Therapeutics Ltd. have bought $0 and sold $0 worth of Chemomab Therapeutics Ltd. stock.
On average, over the past 5 years, insiders at Chemomab Therapeutics Ltd. have bought $2.07M and sold $1.25M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 33 shares for transaction amount of $91 was made by Maryles Joel Michael () on 2022‑05‑24.
List of Insider Buy and Sell Transactions, Chemomab Therapeutics Ltd.
| 2023-01-03 | Sale | director | 336,900 3.61% | $3.58 | $1.21M | -53.74% | ||
| 2023-01-03 | Sale | Chief Scientific Officer | 13,800 0.2073% | $5.03 | $69,370 | -53.74% | ||
| 2022-11-16 | Sale | Chief Scientific Officer | 582,023 4.6768% | $2.08 | $1.21M | -32.24% | ||
| 2022-11-16 | Sale | director | 2,409 0.0186% | $2.00 | $4,818 | -32.24% | ||
| 2022-05-24 | 33 0.0003% | $2.76 | $91 | -20.36% | ||||
| 2022-05-18 | 2,000 0.0183% | $3.19 | $6,380 | -26.14% | ||||
| 2022-03-18 | 500 0.0043% | $4.36 | $2,180 | -37.28% | ||||
| 2022-03-16 | Executive VP, CFO & COO | 250 0.0017% | $3.30 | $825 | -32.22% | |||
| 2022-03-14 | 2,000 0.0186% | $4.20 | $8,400 | -27.20% | ||||
| 2022-03-14 | Chief Executive Officer | 1,800 0.0158% | $3.98 | $7,164 | -27.20% | |||
| 2022-03-14 | Executive VP, CFO & COO | 250 0.0022% | $4.00 | $1,000 | -27.20% | |||
| 2022-03-11 | 1,200 0.0107% | $4.28 | $5,136 | -30.48% | ||||
| 2021-12-06 | director | 2,000 0.0175% | $7.43 | $14,860 | -54.24% | |||
| 2021-03-16 | 10 percent owner | 230,536 0.6772% | $17.35 | $4M | -83.55% | |||
| 2021-03-16 | director | 2,409 0.0169% | $41.51 | $99,998 | -83.55% |
Insider Historical Profitability
| THIEL PETER | 10 percent owner | 1108509 5.8786% | $1.62 | 1 | 0 | <0.0001% |
| Cohen Neil Harris | director | 10000 0.053% | $1.62 | 4 | 1 | <0.0001% |
| Pfost Dale R | Chief Executive Officer | 1800 0.0095% | $1.62 | 1 | 0 | <0.0001% |
| Marvin Donald | Executive VP, CFO & COO | 1750 0.0093% | $1.62 | 2 | 0 | <0.0001% |
| Maryles Joel Michael | 1433 0.0076% | $1.62 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| OrbiMed | $1.75M | 15.76 | 2.24M | 0% | +$0 | 0.01 | |
| Ikarian Capital LLC | $166,232.00 | 1.5 | 213,392 | 0% | +$0 | 0.02 | |
| Two Sigma | $31,155.00 | 0.28 | 39,994 | -28.97% | -$12,706.14 | <0.0001 | |
| Two Sigma Advisers LP | $29,446.00 | 0.27 | 37,800 | +6.78% | +$1,869.59 | <0.0001 | |
| Kestra Private Wealth Services | $24,337.00 | 0.22 | 31,241 | 0% | +$0 | <0.01 |